Clinical Trial

Resmiterom Efficacy & Safety in Patients With MASH

Name: Resmiterom Efficacy & Safety in Patients With MASH — clinical trial record (NCT07249788)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: REZMASH

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-11-18.

Status change: Not Yet Recruiting → Recruiting 2025-11-25

Trial Details

NCT Number	NCT07249788
Lead Sponsor	Nabiqasim Industries (Pvt) Ltd
Conditions	MASH - Metabolic Dysfunction-Associated Steatohepatitis
Enrollment	165 participants
Start Date	2025-10-17
Primary Completion	2026-10-16 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-12-03